Navigation Links
Lilly Declares Fourth-Quarter Dividend
Date:10/19/2009

INDIANAPOLIS, Oct. 19 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2009 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first three quarters of 2009 and brings the total annual dividend for 2009 to $1.96 per share.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

The dividend is payable December 10, 2009, to shareholders of record at the close of business on November 13, 2009.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY

SOURCE Eli Lilly and Company


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries
2. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
5. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
6. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
9. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
10. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
11. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
Breaking Medicine News(10 mins):